StreetInsider.com News Articles

Vector Science and Therapeutics Corp. (TSXV: PAIN) Files Provisional Patent Application on Integrated Platform for Orthopedic Tissue Regeneration Using Peptides

Thu, 20 Aug 2026 07:30:00 -0400

Platform combines regenerative peptides with autologous platelet-rich biologics, alongside adjunct formulations designed to avoid interfering with the body's own repair cells

MEQUON, Wis., Aug. 20, 2026 /PRNewswire/ -- Vector Science and Therapeutics Corp. ("Vector" or the "Company") (TSXV: PAIN) today announced that it has filed a provisional patent application with the United States Patent and Trademark Office covering an integrated platform intended to improve tissue healing across orthopedic surgical care.

Vector Science and Therapeutics Corp. (TSXV: PAIN) Files Provisional Patent Application on Integrated Platform for Orthopedic Tissue Regeneration Using Peptides

Thu, 20 Aug 2026 07:30:00 -0400

Platform combines regenerative peptides with autologous platelet-rich biologics, alongside adjunct formulations designed to avoid interfering with the body's own repair cells

Vector Science and Therapeutics Corp. (TSXV: PAIN) Files Provisional Patent Application on Integrated Platform for Orthopedic Tissue Regeneration Using Peptides

Thu, 20 Aug 2026 07:30:00 -0400

Platform combines regenerative peptides with autologous platelet-rich biologics, alongside adjunct formulations designed to avoid interfering with the body's own repair cells

Vector Science and Therapeutics Corp. (TSXV: PAIN) Files Provisional Patent Application on Integrated Platform for Orthopedic Tissue Regeneration Using Peptides

Thu, 20 Aug 2026 07:30:00 -0400

Platform combines regenerative peptides with autologous platelet-rich biologics, alongside adjunct formulations designed to avoid interfering with the body's own repair cells

Vector Science and Therapeutics Corp. (TSXV: PAIN) Files Provisional Patent Application on Integrated Platform for Orthopedic Tissue Regeneration Using Peptides

Thu, 20 Aug 2026 07:30:00 -0400

Platform combines regenerative peptides with autologous platelet-rich biologics, alongside adjunct formulations designed to avoid interfering with the body's own repair cells

Vector Science and Therapeutics Corp. (TSXV: PAIN) Files Provisional Patent Application on Integrated Platform for Orthopedic Tissue Regeneration Using Peptides

Thu, 20 Aug 2026 07:30:00 -0400

Platform combines regenerative peptides with autologous platelet-rich biologics, alongside adjunct formulations designed to avoid interfering with the body's own repair cells

Vector Science and Therapeutics Corp. (TSXV: PAIN) Files Provisional Patent Application on Integrated Platform for Orthopedic Tissue Regeneration Using Peptides

Thu, 20 Aug 2026 07:30:00 -0400

Platform combines regenerative peptides with autologous platelet-rich biologics, alongside adjunct formulations designed to avoid interfering with the body's own repair cells

Vector Science and Therapeutics Corp. (TSXV: PAIN) Files Provisional Patent Application on Integrated Platform for Orthopedic Tissue Regeneration Using Peptides

Thu, 20 Aug 2026 07:30:00 -0400

Platform combines regenerative peptides with autologous platelet-rich biologics, alongside adjunct formulations designed to avoid interfering with the body's own repair cells

/C O R R E C T I O N -- Vector Sciences & Therapeutics/

Tue, 18 Aug 2026 07:55:00 -0400

In the news release, Verlytix Launches as a Related Company to LyoGenesis Manufacturing, issued 18-Aug-2026 by Vector Sciences & Therapeutics over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details at the end:

Verlytix Launches as a Related Company to LyoGenesis Manufacturing

Verlytix is applying its analytical and quality testing capabilities to peptide testing in support of Vector Science & Therapeutics, alongside its existing pharmaceutical testing business

MEQUON, Wis., Aug. 19, 2026 /PRNewswire/ -- Verlytix, a global contract testing laboratory

/C O R R E C T I O N -- Vector Sciences & Therapeutics/

Tue, 18 Aug 2026 07:55:00 -0400

Verlytix Launches as a Related Company to LyoGenesis Manufacturing

Verlytix is applying its analytical and quality testing capabilities to peptide testing in support of Vector Science & Therapeutics, alongside its existing pharmaceutical testing business

MEQUON, Wis., Aug. 19, 2026 /PRNewswire/ -- Verlytix, a global contract testing laboratory

/C O R R E C T I O N -- Vector Sciences & Therapeutics/

Tue, 18 Aug 2026 07:55:00 -0400

Verlytix Launches as a Related Company to LyoGenesis Manufacturing

Verlytix is applying its analytical and quality testing capabilities to peptide testing in support of Vector Science & Therapeutics, alongside its existing pharmaceutical testing business

MEQUON, Wis., Aug. 19, 2026 /PRNewswire/ -- Verlytix, a global contract testing laboratory

/C O R R E C T I O N -- Vector Sciences & Therapeutics/

Tue, 18 Aug 2026 07:55:00 -0400

Verlytix Launches as a Related Company to LyoGenesis Manufacturing

Verlytix is applying its analytical and quality testing capabilities to peptide testing in support of Vector Science & Therapeutics, alongside its existing pharmaceutical testing business

MEQUON, Wis., Aug. 19, 2026 /PRNewswire/ -- Verlytix, a global contract testing laboratory

Vector Science signs 10-year manufacturing deal with LyoGenesis

Mon, 17 Aug 2026 07:45:13 -0400

Vector Science and Therapeutics Corp. (TSXV: PAIN) announced that its subsidiary, Vector Science and Therapeutics Operating Corp., has entered into an amended and restated exclusive manufacturing agreement with LyoGenesis Holdings LLC, effective Aug. 13, 2026.

The agreement, which amends a prior deal dated July 6, 2026, has an initial term of 10 years and automatically renews in successive one-year terms unless terminated. LyoGenesis Plus 1 LLC, the manufacturing subsidiary of LyoGenesis, will serve as the exclusive manufacturer of Vector's lyophilized peptide-based pharmaceutical products at its facility in Mequon, Wisconsin, under U.S. Current Good Manufacturing Practices (cGMP).

Quality testing and batch approval will

Vector Science signs 10-year manufacturing deal with LyoGenesis

Mon, 17 Aug 2026 07:45:13 -0400

Quality testing and batch approval will

Vector Science signs 10-year manufacturing deal with LyoGenesis

Mon, 17 Aug 2026 07:45:13 -0400

Quality testing and batch approval will

Vector Science signs 10-year manufacturing deal with LyoGenesis

Mon, 17 Aug 2026 07:45:13 -0400

Quality testing and batch approval will

Vector Science and Therapeutics Corp. Signs Amended, 10-Year Manufacturing and Testing Agreement with LyoGenesis Holdings